TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
Nature Communications (2017) - Comments
pubmed: 28276427  doi: 10.1038/ncomms14687  issn: 2041-1723 

Richard Hill, Patricia A. Madureira, Bibiana Ferreira, Inês Baptista, Susana Machado, Laura Colaço, Marta Dos Santos, Ningshu Liu, Ana Dopazo, Selma Ugurel, Angyal Adrienn, Endre Kiss-Toth, Murat Isbilen, Ali O. Gure, Wolfgang Link